Quality of life strategy identify treatments for cancer as chronic disease,
after hyperthermia achieves local control in about 6 weeks. Treatments sustain
qualify of life through synergy with natural immunity.from patients lifestyle
of vigorous exercise.
.. Status:
Begin hyperthermia with lower dose radiation scheduled February 19,
2009
.. Treatments to date:
Left breast lumpectomy and sentinal node disection 2002
Adriamycin/Cytoxan 2002
Radiation 2002
Taxotere 2002
Taxol/Avastin 2004
Adriamycin/Cytoxan 2005
Taxotere/Xeloda 2005
Mastectomy 2005
Taxotere/Xeloda 2006
Carboplatin/Erbitux (cetuximab) 2007 and 2008
Sutent/Methotrexate/Cytoxan 2008
Hyperthermia with lower dose radiation 2009
.. Treatment Options (generally in the order of importance) .. MD Anderson IBC Research Center
Evaluation and Treatment (on-site or in conjunction with
Kaiser oncologists) at the top inflammatory breast cancer
center in the country: MD Anderson Cancer Center,
Houston, TX
.. Dr. Massimo Cristofanilli is the co-director of their IBC
clinic; 1-877-MDA-6789
In December 2008, held the first ever IBC
conference; if you are interested, I could obtain the
research presented at this conference
They could also give you a second opinion on the
lymph node biopsy done 11/7/08 (no appointment
required usually)
..
In 5% - 10% of cases, initial biopsy analysis will be incorrect. Review
therefore yields additional treatment options in some cases. The patient
requests the biopsy slide from the laboratory at Kaiser, similiar to getting a
second opinion, and mail to the MD Anderson
Participation in clinical trials (but must meet their eligibility
requirements)..
Phase I/II study of GM-CSF vaccine therapy with
interferon alfa and Cytoxan; Good Samaritan
Hospital, Los Angeles, Ca; Charles Wiseman, MD;
primary investigator; contact: Cary H. Gota, MD at
213-977-1214; Dr. Wiseman has been doing cancer
immunotherapy for many, many years
Phase I/II study of Rexin-G, a viral vector oncocidal
gene therapy for breast cancer; Epeius Clinical
Research Unit; San Marino, Ca; Sant Chawla,
primary investigator; 310-552-9999; the theory
behind this vaccine is impeccable
..
Phase II study of Casodex (Bicalutamide) in
androgen receptor-positive, triple-negative BC;
Memorial Sloan-Kettering Cancer Center, NY;
Clifford Hudis, primary investigator; 212-639-5449; but
tumor must be tested for androgen-receptor first
Phase II study of AZD0530, a Src inhibitor for triple-
negative BC; Memorial Sloan-Kettering Cancer
Center, NY; Dr. Tiffany A. Traina, primary investigator;
212-639-5209
..
Phase IIb study of Gemzar +/-Nexavar: Memorial
Sloan-Kettering Cancer Center, NY; Clifford Hudis,
primary investigator; 212-639-5449; Nexavar as anti-
VEGF activity like Avastin but without the blood clot
risk; of note, Nexavar is similar to but not the same as
Sutent (sunitinib used for Millie's 5th relapse beginning
on November 13, 2008, and ended on January 22, 2009)
..
Phase 1 study of PARP inhibitor; this drug is showing
exciting activity against BRCA-positive tumors (most
BRCA+ tumors are triple negative); multiple studies in
multiple locations:
National Cancer Insitute, Bethesda, MD;
clinicaltrials.gov identifier NCT00749502,
NCT00553189, NCT00647062
..
Tampa, FL sponsored by Merck;
clinicaltrials.gov identifier NCT00749502;
contact 888-577-8839
Phase I study of CNF2024, an oral HSP 90 inhibitor;
Memorial Sloan-Kettering Cancer Center, NY ; Dr.
Shanu Modi, primary investigator; 212-639-5243
..
Phase I study of Vaccinia virus injection into
superficial tumors; University of Pittsburgh Cancer
Institute; Herbert J. Zeh, MD, PhD, primary
investigator; 412-692-2852 or
.. Vaccine clinical trials - new immunotherapy programs
Phase I study of dendritic cell vaccine; Southern
Cancer Center, Mobile, AL; Paul Schwarzenberger,
MD, primary investigator; contact Judy Motlow
251-433-9899
..
Phase I study of mammaglobin-A DNA vaccine;
Washington University; St. Louis, MO; primary
investigator is William Gillanders, M.D. at 314-7470072
or very exciting
possibility but not quite recruiting yet
Phase I trial of Ad-sig-hMUC-1/ecdCD40L vaccine;
Jonsson Cancer Center, UCLA; Sara Hurvitz, MD
primary investigator; 888-798-0719; very exciting as
Millie's cancer is very likely to MUC-positive since it is
CA 15-3 positive
..
Phase II study of vaccine with Aldesleukin; University
of Minnesota; Tufia Haddad, MD, primary
investigator; 612-624-2620
Phase 1 study of CDX-1307 and hCG-B vaccine;
Duke University, Durham, NC: Micheal Morse, MD,
primary investigator; contact Nikki Adams, RN at
313-916-8862; University of Pennsylvania,
Philadelphia, PA; Angela DeMichelle, MD, primary
investigator; contact Adri Recio, RN at 215-573-6760
Novel therapy outside of clinical trials (using interventions
with at least some clinical data support):
..
Autologous vaccine (made from the patient’s live
tumor); Gustavo Moviglia, MD; main lab: Buenos
Aires, Argentina; also has facilities in San Salvador;
not covered by any U.S. insurance; expensive
Chemosensitivity testing of live tumor to determine
which chemotherapy or targeted agent is most
active against the tumor; Rational Therapeutics;
Robert Nagourney, MD, medical director; contact
Shari Burt at (562) 989-6455 x103
..
Molecular profile of tumor using paraffin-preserved
tissue from previous biopsy or fresh live tumor; this
test may help you find the cancer's Achilles heel;
Caris/Molecular Profile Institute; (602) 358-8900; ask
about their program where they don't charge you
even if your insurance company won't cover it
San Antonio Breast Cancer Conference 12/2008;
Abstract #2119 from MD Anderson; clomipramine, a
commonly prescribed anti-depressant, targets the
protein GSTpi which is found consistently and in high
concentrations on triple-negative breast cancer cells
..
San Antonio Breast Cancer Conference 12/2008;
Abstract #3118 from MD Anderson; datasinib
showed single-agent activity in women with
advanced triple-negative breast cancer
***Please note above research assumes the cancer is HER2negative.
The definitive test result (a FISH analysis done on the
lymph node biopsy of 11/7/08) was not noted in the records.
..
Sincerely,